Compare Amphastar Pharmaceuticals Inc (AMPH) vs Philip Morris International Inc. (PM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Philip Morris International (PM) trades at $181.62, up 0.25% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 26.74% net income margin. However, a recent $500 million impairment charge and lowered profit guidance due to cost pressures and currency swings present near-term headwinds. The stock is near the analyst consensus price target of $194, with support at $179 and resistance at $185.

The outlook for PM is cautiously optimistic, driven by its strong brand portfolio, including IQOS, and consistent cash flow generation. Investment opportunities lie in its dividend yield and potential for margin recovery. Key risks include regulatory challenges, illicit market growth in Europe, and ongoing cost inflation. Analyst consensus remains bullish, but investors should monitor execution against revised guidance.